Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Forum of Clinical Oncology
Volume 7 (2016): Issue 1 (March 2016)
Open Access
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
Alexios Matikas
Alexios Matikas
and
Sofia Aggelaki
Sofia Aggelaki
| Sep 17, 2016
Forum of Clinical Oncology
Volume 7 (2016): Issue 1 (March 2016)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research Article
Published Online:
Sep 17, 2016
Page range:
17 - 27
Received:
Feb 16, 2016
Accepted:
Feb 16, 2016
DOI:
https://doi.org/10.1515/fco-2015-0021
Keywords
NSCLC
,
PD-1
,
PD-L1
,
Nivolumab
,
Pembrolizumab
© 2016
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.